Cite
HARVARD Citation
Oaknin, A. et al. (n.d.). 385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study. International journal of gynecological cancer. pp. A39-A40. [Online].